sorafenib
Selected indexed studies
- Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway. (Cell Prolif, 2022) [PMID:34811833]
- Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. (Theranostics, 2021) [PMID:33859758]
- Sorafenib. (Curr Opin Oncol, 2006) [PMID:16988583]
_Worker-drafted node — pending editorial review._
Connections
sorafenib is a side effect of
Sources
- Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. (2021) pubmed
- Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway. (2022) pubmed
- Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. (2021) pubmed
- Sorafenib. (2006) pubmed
- Sorafenib-induced cardiovascular toxicity: A cause for concern. (2025) pubmed
- SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. (2023) pubmed
- Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial. (2024) pubmed
- Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. (2020) pubmed
- Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. (2024) pubmed
- Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation. (2025) pubmed